RxDoctor Payments Data

Matthew Baugh, MD

Pulmonary Disease · Westmont, ILNPI 1942309125

Payments from drug & device makers

$8,195in general payments, 2019–2025

Across 21 payments — averaging $390.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Veran Medical Technologies, Inc.$842
  • Boehringer Ingelheim$122
  • EMD Serono, Inc.$102
  • Takeda Pharmaceuticals U.S.A., Inc.$18

What the payments were for

  • Travel & lodging$1,55519%
  • Food & beverage$6398%
  • Education$6,00073%

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,195 in reported general payments places this provider in the 70th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$339,890
Medicare patients
1,068
Services billed
5,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter122$174,619
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr88$88,371
Breo ElliptaFluticasone/Vilanterol75$55,638
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$44,741
Arnuity ElliptaFluticasone Furoate67$29,767
Spiriva RespimatTiotropium Bromide18$25,739
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$17,943
SymbicortBudesonide/Formoterol Fumarate26$13,649
Incruse ElliptaUmeclidinium Bromide18$9,562
Albuterol Sulfate HfaAlbuterol Sulfate237$8,479
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$8,118
Wixela InhubFluticasone Propion/Salmeterol22$4,925
Advair DiskusFluticasone Propion/Salmeterol11$4,297
Ventolin HfaAlbuterol Sulfate29$2,804
Azithromycin36$705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$122$43,68139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Westmont

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →